Physician profile
Michelle A Bussmann
NPI 1811097579
$1,037.62
in general payments reported to CMS, 2019-2025
24 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $65.73 · 2022: $18.97 · 2023: $270 · 2024: $278 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $719.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $136.62 | 2019 | |
| Genzyme Corporation | $133.92 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $126.81 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $92.72 | 2020-2025 | Otezla |
| Leo Pharma INC. | $83.03 | 2023-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $47.32 | 2023-2024 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $42.00 | 2024 | Opzelura |
| Lilly USA, LLC | $34.79 | 2024-2025 | Ebglyss, Taltz |
| Pfizer INC. | $33.88 | 2023-2024 | |
| Dermavant Sciences, INC. | $32.84 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $32.20 | 2023 | Sotyktu |
| Celgene Corporation | $29.12 | 2019 | |
| Smith+Nephew, INC. | $26.97 | 2024-2025 | Collagenase Santyl |
| Abbvie INC. | $25.05 | 2024 | |
| Ucb, INC. | $22.95 | 2024 | Bimzelx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.35 | 2024 | Spevigo |
| Novartis Pharmaceuticals Corporation | $18.63 | 2025 | |
| Sun Pharmaceutical Industries INC. | $14.88 | 2019 | |
| Biofrontera INC. | $14.60 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Arcutis Biotherapeutics, INC. | $14.49 | 2024 | Zoryve |
| Galderma Laboratories, L.P. | $13.73 | 2025 | Nemluvio |
| Verrica Pharmaceuticals INC. | $13.51 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $13.39 | 2023 | Valchlor |
| Dermira, INC. | $12.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Bussmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.